AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16947035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient evaluation of treatment success
Number of subjects: 90
Study 16947035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age
Number of subjects: 90
Study 15733984 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial lenses
Number of subjects: 150
Study 15733984 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 150
Study 15733984 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 150
Study 11463600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (250 mg twice per day)
Number of subjects: 15
Study 11463600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9875685 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin (4 mg/kg/day)
Number of subjects: 43
Study 9875685 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily tobramycin (4 mg/kg/day)
Number of subjects: 43
Study 7742607 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose rate brachytherapy
Number of subjects: 0
Study 7742607 — intervention group
Group type: COMPARATOR
Intervention: Lower dose rate brachytherapy
Number of subjects: 0
Study 2607521 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 52
Study 2607521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 4574641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 36
Study 4574641 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 36
Study 30855722 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 mcg/kg/min
Number of subjects: 50
Study 30855722 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.3 mcg/kg/min
Number of subjects: 50
Study 28904310 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) type A injections
Number of subjects: 11
Study 28904310 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (control group)
Number of subjects: 11
Study 26531275 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 50
Study 26531275 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 50
Study 23358983 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily)
Number of subjects: 333
Study 23358983 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg twice daily) plus Amoxicillin/Clavulanic acid (1,000 mg twice daily)
Number of subjects: 333
Study 23358983 — intervention group
Group type: COMPARATOR
Intervention: Both arms (Moxifloxacin and Combination Therapy)
Number of subjects: 333
Study 23358983 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 333
Study 21538382 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine (TMZ) monotherapy
Number of subjects: 11
Study 19135286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine coverage in the neighborhood
Number of subjects: 0
Study 19135286 — intervention group
Group type: COMPARATOR
Intervention: Placebo incidence
Number of subjects: 0
Study 17587254 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injected subcutaneous interferon (IFN)‐beta‐1a 22 microg
Number of subjects: 28
Study 15822545 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT), 6 hours daily training for 2 weeks
Number of subjects: 69
Study 15822545 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment, bimanual-upper-extremity training for 2 weeks
Number of subjects: 69
Study 10896237 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer generated induction system (DAWN AC INDUCTION)
Number of subjects: 101
Study 10896237 — intervention group
Group type: COMPARATOR
Intervention: Manual dosing using a locally defined algorithm
Number of subjects: 101
Study 9462992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0
Study 8238153 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 700
Study 8238153 — intervention group
Group type: COMPARATOR
Intervention: Traditional labor management
Number of subjects: 700
Study 4028632 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (180 gm) in divided doses over 24 hours
Number of subjects: 4
Study 4028632 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 4
Study 27499018 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30U/kg
Number of subjects: 19
Study 27499018 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60U/kg
Number of subjects: 19
Study 27499018 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa dose adjusted
Number of subjects: 19
Study 28132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and leucine-enriched whey protein medical nutrition drink for 13 weeks
Number of subjects: 380
Study 28132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline 25(OH)D concentrations and dietary protein intake
Number of subjects: 380
Study 28132725 — intervention group
Group type: COMPARATOR
Intervention: Lower 25(OH)D concentrations
Number of subjects: 380
Study 28132725 — intervention group
Group type: COMPARATOR
Intervention: Lower protein intake (g/kg/day)
Number of subjects: 380
Study 28132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 25(OH)D status or protein intake
Number of subjects: 380
Study 26687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose imatinib
Number of subjects: 434
Study 26687836 — intervention group
Group type: EXPERIMENTAL
Intervention: KIT exon 11 mutations at codons 557-558
Number of subjects: 434
Study 26466440 — intervention group
Group type: EXPERIMENTAL
Intervention: CEREC crowns produced using CAD-CAM technology
Number of subjects: 10
Study 26466440 — intervention group
Group type: COMPARATOR
Intervention: Ceramo-Metal Crowns produced using a conventional procedure
Number of subjects: 10
Study 23075030 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily breakfast consumption
Number of subjects: 1814
Study 23075030 — intervention group
Group type: COMPARATOR
Intervention: Breakfast consumption frequency
Number of subjects: 1814
Study 20635775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 0
Study 20635775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 17452544 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography post-AMI
Number of subjects: 0
Study 17452544 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy post-AMI
Number of subjects: 0
Study 15177813 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural listening condition
Number of subjects: 40
Study 15177813 — intervention group
Group type: COMPARATOR
Intervention: Left ear only listening condition
Number of subjects: 40
Study 15177813 — intervention group
Group type: COMPARATOR
Intervention: Right ear only listening condition
Number of subjects: 40
Study 14764998 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AD
Number of subjects: 48
Study 14764998 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 48
Study 10574598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HP infection
Number of subjects: 150
Study 10574598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HP-infected patient group
Number of subjects: 150
Study 10574598 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 150
Study 8665034 — intervention group
Group type: EXPERIMENTAL
Intervention: FK224 (4 mg)
Number of subjects: 10
Study 8665034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 2062984 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 30 mg
Number of subjects: 8
Study 2062984 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (3.75, 7.5, 15 and 30 mg)
Number of subjects: 8
Study 2062984 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (7.5, 15, 30 and 60 mg)
Number of subjects: 8
Study 2062984 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (5, 10, 20 and 40 mg)
Number of subjects: 8
Study 2062984 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine and methylphenidate
Number of subjects: 8
Study 6135526 — intervention group
Group type: EXPERIMENTAL
Intervention: RX781094 (0.2 microgram/kg intravenously)
Number of subjects: 0
Study 3964335 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg N-butylscopolaminium bromide (Buscopan)
Number of subjects: 12
Study 3964335 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg N-butylscopolaminium bromide (Buscopan)
Number of subjects: 12
Study 3964335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3964335 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butylscopolaminium bromide (Buscopan)
Number of subjects: 12
Study 30098403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod with mashed potatoes (high GI carbohydrate)
Number of subjects: 23
Study 30098403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod with wholegrain pasta (low GI carbohydrate)
Number of subjects: 23
Study 30098403 — intervention group
Group type: EXPERIMENTAL
Intervention: Veal with mashed potatoes (high GI carbohydrate)
Number of subjects: 23
Study 30098403 — intervention group
Group type: EXPERIMENTAL
Intervention: Veal with wholegrain pasta (low GI carbohydrate)
Number of subjects: 23
Study 30098403 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with high GI carbohydrates
Number of subjects: 23
Study 30098403 — intervention group
Group type: COMPARATOR
Intervention: Meals with low GI carbohydrates
Number of subjects: 23
Study 27809891 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1200 mg/day
Number of subjects: 138
Study 27809891 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg/day
Number of subjects: 138
Study 25616100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic-guided warfarin treatment
Number of subjects: 100
Study 25616100 — intervention group
Group type: COMPARATOR
Intervention: Non-PGx therapy (control)
Number of subjects: 100
Study 23143737 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 101
Study 23143737 — intervention group
Group type: COMPARATOR
Intervention: Standard, left-lateral positioning
Number of subjects: 101
Study 20518168 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle on Governor Vessel and point Jiaji (EX-B 2) with routine rehabilitation method
Number of subjects: 60
Study 20518168 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation method (Bobath + Tuina + scalp acupuncture)
Number of subjects: 60
Study 18381308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine block
Number of subjects: 42
Study 18381308 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 42
Study 16884581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Web-based intervention plus information
Number of subjects: 0
Study 16884581 — intervention group
Group type: COMPARATOR
Intervention: Information website only (Control)
Number of subjects: 0
Study 14550694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 352
Study 14550694 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (control)
Number of subjects: 352
Study 11012478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (RACM)
Number of subjects: 221
Study 11012478 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (RAC)
Number of subjects: 221
Study 11012478 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (OAC)
Number of subjects: 221
Study 11012478 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (OACM)
Number of subjects: 221
Study 8648285 — intervention group
Group type: EXPERIMENTAL
Intervention: Test question asking about the probability of E given C (p(E/C))
Number of subjects: 0
Study 8648285 — intervention group
Group type: EXPERIMENTAL
Intervention: Test question asking about the probability of E given some alternative cause (p(E/C'))
Number of subjects: 0
Study 8648285 — intervention group
Group type: EXPERIMENTAL
Intervention: Test question asking about p(C/E)
Number of subjects: 0
Study 8648285 — intervention group
Group type: EXPERIMENTAL
Intervention: Test question asking about p(C/E')
Number of subjects: 0
Study 8648285 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions where neither causes nor effects competed
Number of subjects: 0
Study 1728612 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (patients with intramural metastasis)
Number of subjects: 60
Study 1728612 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy or chemotherapy after surgery
Number of subjects: 60
Study 6731670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6731670 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole with a meal
Number of subjects: 29
Study 6731670 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole 3 or more hours after or before a meal
Number of subjects: 29
Study 6731670 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (both groups)
Number of subjects: 29
Study 31941574 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-promoting interventions (individual and group formats, more than 12 sessions)
Number of subjects: 2912
Study 31941574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions based on positive psychology, supportive-expressive group therapy, behavioral therapy, or mindfulness
Number of subjects: 2912
Study 29481636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in children with mild to moderate CKD (ERGO study)
Number of subjects: 80
Study 29481636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in children with advanced CKD (4C study)
Number of subjects: 80
Study 29481636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in total cohort
Number of subjects: 80
Study 29481636 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched children not receiving vitamin D)
Number of subjects: 80
Study 27411698 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro injected into lipohypertrophic tissue (LHT)
Number of subjects: 13
Study 27411698 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro injected into normal adipose tissue (NAT)
Number of subjects: 13
Study 24676906 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic subjects
Number of subjects: 0
Study 24676906 — intervention group
Group type: COMPARATOR
Intervention: Neurotypical control subjects
Number of subjects: 0
Study 24676906 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic males
Number of subjects: 0
Study 24676906 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 22512632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled inactivated Mycobacterium phlei
Number of subjects: 0
Study 22512632 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol xinafoate and fluticasone propionate powder (Seretide)
Number of subjects: 0
Study 20506122 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 455
Study 20506122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 455
Study 20506122 — intervention group
Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 455
Study 20506122 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectations communication style
Number of subjects: 455
Study 20506122 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral expectations communication style
Number of subjects: 455
Study 17654188 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 690
Study 17654188 — intervention group
Group type: COMPARATOR
Intervention: Intent to conserve membranes
Number of subjects: 690
Study 16276244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drug therapy aimed at raising HDL-cholesterol
Number of subjects: 0
Study 16276244 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin and well-tolerated fibrates as adjunct to statins or primary therapy
Number of subjects: 0
Study 16276244 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches
Number of subjects: 0
Study 11888042 — intervention group
Group type: EXPERIMENTAL
Intervention: Community action interventions including school curricula, parent involvement, peer leadership, and community task forces during Phase 1 (1991-1994) and classroom curriculum, parent education, print media, youth development, and community organizing during Phase 2 (1996-1998).
Number of subjects: 0
Study 11888042 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention during the Interim Phase (1994-1996).
Number of subjects: 0
Study 11888042 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual student surveys, alcohol purchase attempts by young-looking buyers, and parent telephone surveys.
Number of subjects: 0
Study 9622166 — intervention group
Group type: COMPARATOR
Intervention: modified fetal biophysical profile (mFBP)
Number of subjects: 494
Study 9622166 — intervention group
Group type: EXPERIMENTAL
Intervention: external vibratory acoustic stimulation with modified fetal biophysical profile (VAS/mFBP)
Number of subjects: 494
Study 9622166 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS/mFBP
Number of subjects: 494
Study 7619649 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 10
Study 7619649 — intervention group
Group type: COMPARATOR
Intervention: D-glucose
Number of subjects: 10
Study 2569309 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (Kerlone)
Number of subjects: 0
Study 2569309 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (xipamide-triamterene combination, Neotri)
Number of subjects: 0
Study 322649 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.1%
Number of subjects: 20
Study 322649 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 20
Study 322649 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 20
Study 322649 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 1.0%
Number of subjects: 20
Study 31074532 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified salting-out method
Number of subjects: 0
Study 31074532 — intervention group
Group type: COMPARATOR
Intervention: QIAamp® DNA Blood Midi Kit
Number of subjects: 0
Study 31074532 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified QIAamp® DNA Blood Midi Kit
Number of subjects: 0
Study 28252269 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS) followed by Pipelle® sampling
Number of subjects: 2
Study 28252269 — intervention group
Group type: COMPARATOR
Intervention: Pipelle® sampling followed by saline infusion sonography (SIS)
Number of subjects: 2
Study 26590673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Number of subjects: 1366
Study 26590673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Number of subjects: 1366
Study 26590673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1366
Study 26590673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1366
Study 25082918 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (MOD group)
Number of subjects: 21
Study 25082918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HIGH group)
Number of subjects: 21
Study 22338103 — intervention group
Group type: EXPERIMENTAL
Intervention: E/S + extended-release niacin (N; titrated to 2 g)
Number of subjects: 942
Study 22338103 — intervention group
Group type: COMPARATOR
Intervention: E/S
Number of subjects: 942
Study 19776570 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with 20 ml of 100 mg F/l NaF mouthwash after brushing with fluoridated toothpaste (Regime B)
Number of subjects: 23
Study 19776570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with 1 g of 1,450 microg F/g NaF toothpaste followed by rinsing for 5 s with 10 ml water (Regime A)
Number of subjects: 23
Study 19776570 — intervention group
Group type: COMPARATOR
Intervention: Rinsing with a non-fluoridated mouthwash after brushing with fluoridated toothpaste (Regime C)
Number of subjects: 23
Study 17688918 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique (dissection of bilateral vasa deferentia before placing a retractor)
Number of subjects: 321
Study 17688918 — intervention group
Group type: COMPARATOR
Intervention: Previous method (retraction of vasa deferentia with a retractor)
Number of subjects: 321
Study 15378665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondamtanggamibang (Korean traditional herbal remedy)
Number of subjects: 40
Study 15378665 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 40
Study 11835723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia therapy (MHT) for 4-10 days
Number of subjects: 60
Study 11835723 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 60
Study 11835723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia therapy (MHT)
Number of subjects: 60
Study 9631161 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving blood cholesterol test results at pretest
Number of subjects: 500
Study 9631161 — intervention group
Group type: COMPARATOR
Intervention: Not receiving blood cholesterol test results (control group)
Number of subjects: 500
Study 7883414 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastin HCL
Number of subjects: 28